Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Equity (2018 - 2025)

Inmune Bio's Return on Equity history spans 8 years, with the latest figure at 1.89% for Q3 2025.

  • For Q3 2025, Return on Equity fell 79.0% year-over-year to 1.89%; the TTM value through Sep 2025 reached 1.89%, down 79.0%, while the annual FY2024 figure was 1.23%, 61.0% down from the prior year.
  • Return on Equity for Q3 2025 was 1.89% at Inmune Bio, up from 1.92% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.19% in Q1 2021 and bottomed at 1.92% in Q2 2025.
  • The 5-year median for Return on Equity is 0.49% (2023), against an average of 0.78%.
  • The largest annual shift saw Return on Equity increased 12bps in 2021 before it plummeted -79bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.35% in 2021, then decreased by -21bps to 0.42% in 2022, then crashed by -75bps to 0.73% in 2023, then crashed by -65bps to 1.2% in 2024, then tumbled by -57bps to 1.89% in 2025.
  • Per Business Quant, the three most recent readings for INMB's Return on Equity are 1.89% (Q3 2025), 1.92% (Q2 2025), and 1.34% (Q1 2025).